Chief Operating Officer of the Philogen Group and Board Member of Philochem AG (Philogen discovery center). Graduated in Medicinal Chemistry at La Sapienza University and performed Ph.D. studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of extracranial and brain tumors. Author of more than 20 peer-reviewed publications in international scientific journals and is recipient of the Swiss Brain Tumor Foundation 2021 and of the Pfizer Research Prize 2022.